comparemela.com

Recently, Venus Medtech (Hangzhou) Inc. ("Venus Medtech"), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced the Investigational Device Exemption (IDE) full approval for its in-house developed VenusP-Valve from the U.S. Food and Drug Administration (FDA). VenusP-Valve, thus, has become the first China-developed heart valvular system to be approved by the FDA for clinical trial, setting a new milestone in the global footprint of C

Related Keywords

Denmark ,France ,Switzerland ,Germany ,Japan ,Italy ,Spain ,China ,Greece ,United Kingdom ,Poland ,Eric Zi ,Venus Medtech ,Venus Medtech Hangzhou Inc ,Pre Market Approval ,Medical Devices Regulation ,Executive Director ,General Manager ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.